🎯 Drug Targets

Complement cascade inhibitor or antibody-mediated neutralization

MIRO1-targeting drugs modulate GTPase activity to enhance mitochondrial transport along axons and improve mitochondrial quality control through selective autophagy. By regulating MIRO1's interaction with kinesin motor proteins and PINK1-mediated mitophagy, these compounds restore energy homeostasis and reduce neuronal stress in neurodegenerative diseases.

Small molecule agonists or antagonists of cGAS-STING pathway activation

Calcium-dependent phospholipid binding protein modulator

RAB27A inhibitors would block GTP binding or GTPase activity, preventing the recruitment of effector proteins required for vesicular trafficking and exosome biogenesis. This would reduce the release of extracellular vesicles and potentially modulate intercellular communication in disease states involving excessive exosome-mediated signaling or pathological cargo transfer.

Complement cascade inhibitor or antibody-mediated neutralization

PYCARD acts as a critical adaptor protein in inflammasome activation, facilitating pro-inflammatory caspase-1 recruitment and subsequent IL-1β/IL-18 processing, which contributes to neuroinflammatory processes in neurodegenerative conditions like Alzheimer's and Parkinson's disease. Its protein-protein interaction domains mediate inflammatory signal transduction, potentially amplifying neuronal damage through excessive immune response activation.

Small molecule or antisense-based inhibitors would disrupt SYNCRIP's RNA-binding capability, reducing its ability to facilitate mRNA transport and local protein synthesis, potentially modulating disease pathways in neurological disorders or cancers where SYNCRIP dysfunction is implicated.

Drugs targeting RELN would primarily work by enhancing reelin expression or signaling through its receptors (VLDLR and ApoER2) to promote neuronal migration, synaptic plasticity, and cognitive function. Alternatively, pathway modulators could enhance downstream signaling cascades (Dab1-mediated pathways) to compensate for reelin deficiency or dysfunction.

Prioritized from 1 SciDEX hypotheses, including: Context-Dependent CRISPR Activation in Specific Neuronal Subtypes

No known druggable mechanism

Prioritized from 1 SciDEX hypotheses, including: Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring

Prioritized from 1 SciDEX hypotheses, including: Synthetic Biology Approach: Designer Mitochondrial Export Systems

Prioritized from 1 SciDEX hypotheses, including: Programmable Neuronal Circuit Repair via Epigenetic CRISPR